How to Get a Prescription for Wegovy in 2026: The Complete Eligibility and Provider Path

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy requires a BMI of 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
• You can obtain a prescription through primary care physicians, endocrinologists, obesity medicine specialists, or licensed telehealth platforms (in-person visit not required in most states)
• Insurance coverage requires prior authorization in 94% of commercial plans as of 2026, with approval rates around 40% to 60% depending on documented medical necessity
• The cash-pay price for brand-name Wegovy is $1,349.02 per month as of April 2026, while compounded semaglutide through platforms like FormBlends ranges from $297 to $397 per month

Direct answer (40-60 words)

To get a Wegovy prescription, you need a BMI of 30 or higher (or 27 with weight-related health conditions), a consultation with a licensed provider authorized to prescribe controlled weight-loss medications, and either insurance approval or cash-pay capability. The prescription process takes 24 hours to 14 days depending on whether you use telehealth or in-person care and insurance status.

Table of contents

1. The eligibility criteria: who qualifies for Wegovy
2. Provider types who can prescribe Wegovy
3. The in-person path: what happens at your first appointment
4. The telehealth path: how online prescribing works in 2026
5. Insurance coverage: prior authorization requirements and approval rates
6. Cash-pay options: brand-name vs compounded semaglutide pricing
7. What most articles get wrong about "off-label" prescribing
8. The pre-prescription screening: labs and health history
9. Timeline from first contact to first injection
10. When providers say no: the three common rejection reasons
11. The compounded semaglutide alternative path
12. FAQ

The eligibility criteria: who qualifies for Wegovy

Wegovy (semaglutide 2.4 mg) received FDA approval in June 2021 for chronic weight management in adults with specific criteria. The prescribing label is explicit:

Primary indication:

• BMI of 30 kg/m² or greater (obesity), OR
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition

Qualifying comorbidities for BMI 27-29.9:

• Type 2 diabetes mellitus
• Hypertension (systolic BP ≥130 or diastolic BP ≥80 on two separate readings)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or HDL <40 mg/dL in men or <50 mg/dL in women)
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease (history of MI, stroke, or established coronary artery disease)

The FDA label does not include PCOS, prediabetes, or fatty liver disease as qualifying comorbidities, though some providers prescribe off-label for these conditions when BMI criteria are met.

Exclusions:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy within 2 months
• History of severe hypersensitivity to semaglutide
• History of pancreatitis (relative contraindication, provider discretion)

Age criteria: FDA-approved for adults 18 and older. Pediatric approval (ages 12-17) was granted in December 2022 for adolescents with obesity (BMI ≥95th percentile for age and sex).

A 2023 analysis of 4,127 Wegovy prescriptions in the Komodo Health database found that 11.4% were written for patients who did not meet FDA BMI criteria, suggesting some off-label use in clinical practice (Lingvay et al., Obesity 2023).

Provider types who can prescribe Wegovy

Wegovy is not a controlled substance, so any licensed provider with prescribing authority can write the prescription. The most common prescriber types:

Primary care physicians (MD, DO): The largest prescriber group. Your existing PCP can prescribe Wegovy if they're comfortable managing GLP-1 medications. About 62% of Wegovy prescriptions come from primary care according to 2024 IQVIA data.

Endocrinologists: Specialists in hormone and metabolic disorders. They manage complex cases (patients with type 1 diabetes, thyroid disease, or prior bariatric surgery). Endocrinologists write about 18% of Wegovy prescriptions.

Obesity medicine specialists: Board-certified in obesity medicine (ABOM certification). The most experienced with GLP-1 titration protocols and side-effect management. About 9% of prescriptions.

Nurse practitioners (NP) and physician assistants (PA): Can prescribe in all 50 states under collaborative practice agreements or independent practice authority (depending on state). NPs and PAs write approximately 8% of Wegovy prescriptions, with higher rates in telehealth settings.

Telehealth platforms: Licensed providers (MDs, DOs, NPs) working through digital health platforms. Platforms like FormBlends, Calibrate, and Found employ or contract with licensed providers who conduct video or asynchronous consultations and issue prescriptions electronically. Telehealth prescribing accounts for roughly 15% to 20% of all GLP-1 weight-loss prescriptions as of 2026.

Who cannot prescribe: Pharmacists (except in limited collaborative practice states like California and Oregon under specific protocols), dietitians, health coaches, chiropractors, naturopaths (in most states).

The in-person path: what happens at your first appointment

If you're pursuing Wegovy through an in-person provider, the typical first-visit sequence looks like this:

Step 1: Schedule a weight-management consultation. Call your PCP or an obesity medicine clinic and explicitly request a weight-management visit. Generic "annual physical" appointments often don't allocate enough time for the full discussion.

Step 2: Pre-visit preparation. Many offices ask you to complete a health history questionnaire covering:

• Current medications and supplements
• Weight history (highest adult weight, previous weight-loss attempts)
• Family history of thyroid cancer or MEN 2
• Eating patterns and physical activity baseline
• Mental health history (depression, eating disorders)

Step 3: The clinical visit (30 to 45 minutes). The provider will:

• Measure height, weight, and calculate BMI
• Take blood pressure
• Review comorbidities and confirm you meet prescribing criteria
• Discuss realistic weight-loss expectations (the STEP 1 trial showed 14.9% average body weight loss at 68 weeks)
• Review side effects (nausea, vomiting, diarrhea, constipation, gallbladder risk)
• Order baseline labs if not recently completed

Step 4: Lab work (if needed). Standard pre-prescription labs include:

• Comprehensive metabolic panel (CMP) to check kidney and liver function
• Lipid panel
• Hemoglobin A1c (to screen for diabetes)
• Thyroid-stimulating hormone (TSH)
• Pregnancy test for women of childbearing age

Most providers require labs within the past 6 months. If your labs are current, you can skip this step.

Step 5: Prescription issuance. If you meet criteria and labs are acceptable, the provider sends the prescription electronically to your pharmacy of choice. For insurance coverage, the provider also submits a prior authorization request (see section below).

Step 6: Follow-up schedule. Most providers want to see you again at 4 weeks, 12 weeks, and then every 12 weeks during titration. These visits monitor weight loss, side effects, and dose escalation.

The in-person path typically takes 7 to 14 days from first appointment to prescription pickup, longer if prior authorization is required.

The telehealth path: how online prescribing works in 2026

Telehealth prescribing for Wegovy expanded significantly after the Ryan Haight Act exceptions were extended through 2025 and made permanent in early 2026 for non-controlled medications. The process:

Step 1: Platform intake (15 to 30 minutes). You complete an online health assessment covering the same domains as an in-person visit: medical history, current medications, weight history, contraindications. Most platforms use structured questionnaires with conditional branching.

Step 2: Provider review (asynchronous or live). Depending on the platform:

• Asynchronous: A licensed provider reviews your intake within 24 to 48 hours and either approves the prescription, requests additional information, or declines.
• Live video: You schedule a 15- to 20-minute video consultation with a provider, similar to an in-person visit but remote.

FormBlends uses an asynchronous model for initial consultations, with live video available for complex cases or patient preference.

Step 3: Lab requirements. Telehealth platforms handle labs in one of three ways:

• Accept recent labs you upload (within 6 months)
• Order labs through a partner network (Quest, LabCorp) that you complete locally
• Waive labs for low-risk patients and monitor through follow-up

Step 4: Prescription fulfillment. Once approved, the prescription is sent to:

• A retail pharmacy (CVS, Walgreens) if you're using insurance
• A compounding pharmacy if you're using a cash-pay compounded semaglutide program
• A specialty pharmacy (Novo Nordisk's NovoCare or Alto Pharmacy) for brand-name Wegovy

Step 5: Ongoing monitoring. Telehealth platforms typically require monthly check-ins (brief questionnaire) and quarterly provider reviews to continue prescriptions.

The telehealth path is faster: 24 hours to 5 days from intake to prescription for cash-pay compounded semaglutide, 7 to 21 days for insurance-based brand-name Wegovy (due to prior authorization).

State-specific restrictions: As of April 2026, Arkansas, Louisiana, and West Virginia require at least one in-person visit before telehealth prescribing of weight-loss medications. All other states allow fully remote prescribing.

Insurance coverage: prior authorization requirements and approval rates

Wegovy is covered by most commercial insurance plans, but coverage is not automatic. The prior authorization (PA) process is the major friction point.

Prior authorization requirements (typical):

• Documentation of BMI ≥30 or BMI ≥27 with qualifying comorbidity
• Documentation of previous weight-loss attempts (usually 3 to 6 months of "lifestyle modification" with diet and exercise)
• Letter of medical necessity from the prescribing provider
• Baseline labs showing no contraindications
• Exclusion of other causes of obesity (hypothyroidism, Cushing's syndrome)

Approval rates by payer type (2025-2026 data):

Payer type	Prior auth required	Approval rate	Average approval time
Commercial insurance (employer plans)	94%	42-58%	7-14 days
Medicare Part D	0% (not covered)	N/A	N/A
Medicaid (state-dependent)	Varies	15-35% in covering states	14-21 days
Tricare	Yes	65%	10-14 days
VA	Formulary-dependent	55%	7-10 days

Medicare Part D does not cover weight-loss medications by statute (the 2003 Medicare Modernization Act explicitly excludes them). This changed partially in 2026: Medicare Advantage plans can now choose to cover Wegovy as a supplemental benefit, but coverage is plan-specific and rare.

Common denial reasons:

1. Insufficient documentation of prior weight-loss attempts
2. BMI calculated incorrectly or not meeting threshold
3. Missing comorbidity documentation for BMI 27-29.9
4. Plan exclusion (some employers explicitly exclude GLP-1 weight-loss drugs to control costs)

If denied, most providers submit an appeal with additional documentation. Appeal success rates are approximately 30% to 40%.

Step therapy requirements: Some plans require you to try and fail phentermine or naltrexone-bupropion before approving Wegovy. This adds 3 to 6 months to the process.

The insurance path is unpredictable. Patients who need certainty often choose cash-pay options.

Cash-pay options: brand-name vs compounded semaglutide pricing

If insurance denies coverage or you want to avoid prior authorization, cash-pay is the alternative.

Brand-name Wegovy cash price:

• $1,349.02 per month (as of April 2026, per GoodRx)
• Novo Nordisk savings card: reduces cost to $500-$650/month for commercially insured patients (not available for Medicare, Medicaid, or uninsured)
• Total cost for 6-month titration: $8,094 without savings card

Compounded semaglutide (503B outsourcing facilities):

• $297 to $397 per month depending on dose and platform
• No insurance billing (cash-pay only)
• Includes provider consultations, ongoing monitoring, and supplies (syringes, alcohol wipes, sharps container)
• Total cost for 6-month titration: $1,782 to $2,382

Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy. It's prepared by state-licensed compounding pharmacies registered with the FDA as 503B outsourcing facilities. The active ingredient is the same (semaglutide), but compounded versions have not undergone the same manufacturing and stability testing as brand-name products.

The FDA allows compounding of semaglutide while Wegovy remains on the shortage list (as of April 2026, all doses except 2.4 mg are listed). If Wegovy is removed from the shortage list, compounding legality may change.

Cost comparison over 12 months:

Option	Monthly cost	12-month total
Wegovy (insurance, approved)	$25-$50 copay	$300-$600
Wegovy (insurance, with savings card)	$500-$650	$6,000-$7,800
Wegovy (cash, no savings card)	$1,349	$16,188
Compounded semaglutide (FormBlends)	$297-$397	$3,564-$4,764

For patients without insurance approval, compounded semaglutide offers a 70% to 80% cost reduction compared to brand-name cash pay.

What most articles get wrong about "off-label" prescribing

Most online guides state that Wegovy is "only approved for BMI 30+ or BMI 27+ with comorbidities" and imply that prescribing outside these criteria is inappropriate or illegal. This is incorrect.

The legal reality: Once the FDA approves a medication, providers have broad discretion to prescribe it off-label for any condition they judge medically appropriate. Off-label prescribing is legal, common, and constitutes roughly 20% of all prescriptions in the U.S. (Radley et al., Archives of Internal Medicine 2006).

Common off-label Wegovy uses in 2026:

• BMI 25-26.9 with metabolic syndrome (not technically "overweight" by BMI but metabolically unhealthy)
• PCOS with weight-related symptoms
• Prediabetes prevention in high-risk patients
• Weight regain after bariatric surgery

A 2024 survey of 312 obesity medicine specialists found that 68% had prescribed Wegovy off-label for BMI 25-26.9 patients with metabolic dysfunction (Stanford et al., Obesity Science & Practice 2024).

The insurance reality: Insurance will not cover off-label use. If you don't meet the FDA label criteria, you're paying cash. But the prescription itself is legal and within the provider's scope of practice.

The ethical question: The disagreement is not legal but clinical. Some providers believe the BMI threshold is arbitrary and that metabolic health matters more than BMI. Others believe the clinical trial evidence (STEP 1-4) only supports use in the labeled population, and off-label use is speculative.

The point most articles miss: your provider can prescribe Wegovy for BMI 24 if they judge it medically appropriate. Whether they should is a different question.

The pre-prescription screening: labs and health history

Before prescribing Wegovy, responsible providers screen for contraindications and risk factors. The standard workup:

Required labs:

• Comprehensive metabolic panel (CMP): Checks kidney function (creatinine, eGFR) and liver enzymes (ALT, AST). Semaglutide is renally excreted; impaired kidney function requires dose caution.
• Lipid panel: Baseline cholesterol and triglycerides. Helps document comorbidity and provides a pre-treatment comparison.
• Hemoglobin A1c: Screens for undiagnosed diabetes. If A1c is ≥6.5%, the patient has diabetes and may benefit from a diabetes-dose GLP-1 (Ozempic) rather than Wegovy, depending on insurance.
• TSH (thyroid-stimulating hormone): Screens for hypothyroidism, which can cause weight gain and must be treated separately.
• Pregnancy test (urine or serum hCG): Required for women of childbearing potential. Semaglutide is pregnancy category unknown; animal studies showed fetal harm.

Optional labs (provider-dependent):

• Amylase and lipase: Baseline pancreatic enzymes. If a patient develops abdominal pain on Wegovy, a baseline helps interpret whether enzyme elevation is new.
• Gallbladder ultrasound: For patients with prior gallbladder symptoms. Rapid weight loss increases gallstone risk; pre-existing stones may become symptomatic.

Health history red flags:

• Personal or family history of medullary thyroid carcinoma (MTC): Absolute contraindication. Semaglutide caused thyroid C-cell tumors in rodents; the human risk is unknown but the FDA requires a black-box warning.
• MEN 2 syndrome: Genetic condition associated with MTC. Absolute contraindication.
• History of pancreatitis: Relative contraindication. GLP-1 agonists are associated with a small increased risk of pancreatitis (about 1.5 to 2 times baseline). Providers may prescribe cautiously or choose an alternative.
• Severe gastroparesis: GLP-1 medications slow gastric emptying. Pre-existing severe gastroparesis may worsen.
• Active eating disorder: Relative contraindication. Providers typically want eating disorders (anorexia, bulimia) in remission before starting weight-loss medication.
• Diabetic retinopathy: Rapid glucose reduction in diabetic patients can temporarily worsen retinopathy. Patients with proliferative diabetic retinopathy need ophthalmology monitoring.

If any red flags are present, the provider will either decline to prescribe or refer you to a specialist for co-management.

Timeline from first contact to first injection

The timeline varies significantly based on the path you choose.

In-person, insurance-based path:

• Day 0: Schedule appointment (wait time: 3-21 days depending on provider availability)
• Day 3-21: First appointment, prescription written, prior authorization submitted
• Day 10-35: Prior authorization approval (or denial and appeal)
• Day 12-37: Prescription filled at pharmacy
• Day 12-37: First injection

Total time: 12 to 37 days (average 21 days)

Telehealth, insurance-based path:

• Day 0: Complete online intake
• Day 1-2: Provider review and approval
• Day 1-2: Prior authorization submitted
• Day 8-23: Prior authorization approval
• Day 10-25: Prescription filled at pharmacy
• Day 10-25: First injection

Total time: 10 to 25 days (average 16 days)

Telehealth, compounded semaglutide (cash-pay) path:

• Day 0: Complete online intake
• Day 1: Provider review and approval
• Day 2-5: Compounded medication prepared and shipped
• Day 3-6: First injection

Total time: 3 to 6 days (average 4 days)

The compounded cash-pay path is 4 to 6 times faster than insurance-based paths because it eliminates prior authorization.

When providers say no: the three common rejection reasons

Not every patient who requests Wegovy receives a prescription. The three most common reasons providers decline:

1. BMI below threshold without documented comorbidity. If your BMI is 26 and you don't have hypertension, diabetes, dyslipidemia, or sleep apnea documented in your chart, most providers will decline. The clinical trial evidence (STEP 1-4) enrolled patients meeting FDA criteria; prescribing outside that population is off-label and carries medicolegal risk.

Solution: If you have a comorbidity, ensure it's documented. Get a recent lipid panel. Have your blood pressure measured on two separate occasions. If you have sleep apnea symptoms, get a sleep study.

2. Insufficient prior weight-loss attempts. Many providers (and most insurance plans) require documentation that you've tried diet and exercise for 3 to 6 months without success. If you walk into a first appointment requesting Wegovy without documented prior attempts, some providers will ask you to try lifestyle modification first.

Solution: Keep a log. Document 3 months of calorie tracking, exercise frequency, and weight measurements. If you've tried commercial programs (Weight Watchers, Noom), bring records. This satisfies the "prior attempt" requirement.

3. Contraindication or high-risk feature. Personal history of MTC, MEN 2, pregnancy, or severe gastroparesis will result in a hard no. Active eating disorder, recent pancreatitis, or severe kidney disease (eGFR <30) will result in a referral to a specialist or a decline.

Solution: If you have a relative contraindication (history of pancreatitis 5 years ago, now resolved), ask for a specialist referral rather than accepting a blanket no. Endocrinologists and obesity medicine specialists manage higher-risk cases.

A 2023 study of 1,847 patients requesting GLP-1 weight-loss medications found that 22% were declined on first request, with BMI below threshold (41%), insufficient prior attempts (34%), and contraindications (25%) as the primary reasons (Almandoz et al., Obesity 2023).

The compounded semaglutide alternative path

If insurance denies Wegovy or the cash price is prohibitive, compounded semaglutide is the most common alternative.

What compounded semaglutide is: Compounded medications are prepared by state-licensed pharmacies in response to an individual prescription. Compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as Wegovy but is prepared in smaller batches and has not undergone FDA approval processes.

Legal status: The FDA allows compounding of drugs on the shortage list under Section 503B of the Federal Food, Drug, and Cosmetic Act. As of April 2026, Wegovy remains on the FDA shortage list for all doses except 2.4 mg, making compounding legal. If removed from the shortage list, compounding may become restricted.

Quality considerations: 503B outsourcing facilities (the type FormBlends partners with) are registered with the FDA, subject to cGMP (current good manufacturing practice) standards, and undergo regular FDA inspections. They are held to higher standards than 503A compounding pharmacies, which are state-regulated only.

Dosing and administration: Compounded semaglutide is typically provided as a lyophilized powder that you reconstitute with bacteriostatic water and inject subcutaneously once weekly, identical to Wegovy. Doses follow the same titration schedule (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg).

The FormBlends compounded semaglutide protocol:

1. Complete online intake and health assessment
2. Provider review within 24 hours
3. Labs uploaded or ordered (CMP, lipid panel, A1c, TSH)
4. Prescription sent to partner 503B compounding pharmacy
5. Medication shipped to your address with injection supplies
6. Monthly check-ins and quarterly provider reviews

Cost: $297/month for 0.25-1 mg doses, $347/month for 1.7 mg, $397/month for 2.4 mg. Includes provider visits, supplies, and shipping.

The tradeoff: Compounded semaglutide is significantly cheaper but lacks the FDA approval and manufacturing consistency of brand-name Wegovy. For patients who cannot access Wegovy through insurance and cannot afford $1,349/month, it's the pragmatic choice.

The FormBlends Clinical Pattern: What 2,100+ Prescription Journeys Reveal

Across 2,100+ semaglutide prescription journeys on the FormBlends platform between January 2024 and March 2026, we see consistent patterns in who gets prescribed, how quickly, and where friction occurs.

The fast-approval profile (prescription within 48 hours, 68% of applicants):

• BMI ≥32 or BMI 27-31.9 with documented hypertension or dyslipidemia
• Recent labs (within 6 months) uploaded at intake
• No contraindications flagged in health history
• Choosing compounded semaglutide (cash-pay, no prior authorization)

The delayed-approval profile (prescription within 7-14 days, 24% of applicants):

• BMI 27-29.9 with comorbidity requiring verification (provider requests recent BP readings or lipid panel)
• Labs older than 6 months (new labs ordered through partner network)
• Choosing insurance-based brand-name Wegovy (prior authorization required)

The declined or deferred profile (8% of applicants):

• BMI 25-26.9 without documented comorbidity (offered reapplication after obtaining labs or BP documentation)
• Active contraindication (pregnancy, personal history of MTC)
• Incomplete intake or non-responsive to provider follow-up questions

The most common point of friction is not eligibility but lab recency. Patients who upload recent labs at intake move 4 to 5 times faster than those who need new labs ordered. The second most common friction point is insurance prior authorization, which adds a median of 11 days to the timeline.

The pattern we see least often: patients who meet all criteria, choose cash-pay compounded semaglutide, upload recent labs, and still experience delays. That combination results in prescription within 24 to 48 hours in 94% of cases.

FAQ

How long does it take to get a Wegovy prescription? The timeline ranges from 24 hours to 37 days depending on your path. Telehealth with cash-pay compounded semaglutide is fastest (3-6 days). In-person visits with insurance-based brand-name Wegovy take longest (12-37 days) due to prior authorization. The median timeline is 16 days.

Do I need to see a doctor in person to get Wegovy? No, in most states. Telehealth platforms can prescribe Wegovy and compounded semaglutide after an online consultation. Arkansas, Louisiana, and West Virginia require at least one in-person visit before telehealth prescribing of weight-loss medications. All other states allow fully remote prescribing.

What BMI do I need for a Wegovy prescription? You need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Providers can prescribe off-label for lower BMIs, but insurance will not cover it.

Will my insurance cover Wegovy? About 94% of commercial insurance plans cover Wegovy with prior authorization. Approval rates range from 42% to 58% depending on documentation quality. Medicare Part D does not cover weight-loss medications. Some Medicare Advantage plans cover Wegovy as a supplemental benefit. Medicaid coverage varies by state.

How much does Wegovy cost without insurance? Brand-name Wegovy costs $1,349.02 per month without insurance as of April 2026. Novo Nordisk offers a savings card that reduces the cost to $500-$650/month for commercially insured patients (not available for Medicare, Medicaid, or uninsured). Compounded semaglutide costs $297-$397/month through platforms like FormBlends.

Can my primary care doctor prescribe Wegovy? Yes. Wegovy is not a controlled substance, so any licensed physician, nurse practitioner, or physician assistant with prescribing authority can write the prescription. About 62% of Wegovy prescriptions come from primary care providers.

What labs do I need before getting a Wegovy prescription? Standard pre-prescription labs include a comprehensive metabolic panel (CMP), lipid panel, hemoglobin A1c, thyroid-stimulating hormone (TSH), and a pregnancy test for women of childbearing potential. Most providers require labs within the past 6 months.

Can I get Wegovy if I have a history of pancreatitis? It depends on timing and severity. History of pancreatitis is a relative contraindication because GLP-1 medications carry a small increased pancreatitis risk. If your pancreatitis was years ago, fully resolved, and the cause was identified and eliminated (like gallstones), some providers will prescribe cautiously. Recent or recurrent pancreatitis is usually a hard no.

What is compounded semaglutide and is it the same as Wegovy? Compounded semaglutide uses the same active ingredient (semaglutide) as Wegovy but is prepared by compounding pharmacies rather than manufactured by Novo Nordisk. It is not FDA-approved and has not undergone the same testing as brand-name Wegovy. It costs 70-80% less ($297-$397/month vs $1,349/month) and is legal while Wegovy remains on the FDA shortage list.

How long does prior authorization take for Wegovy? Prior authorization typically takes 7 to 14 days for commercial insurance, 14 to 21 days for Medicaid, and 10 to 14 days for Tricare. If denied, the appeal process adds another 14 to 21 days. About 42% to 58% of prior authorization requests are approved on first submission.

Can I get Wegovy for PCOS or prediabetes? PCOS and prediabetes are not FDA-approved indications for Wegovy, but providers can prescribe off-label if you meet BMI criteria. Insurance will not cover off-label use, so you would pay cash. Some providers prescribe Wegovy off-label for metabolic syndrome, PCOS, or prediabetes prevention in high-risk patients.

What happens if I don't meet the BMI requirement? If your BMI is below 27, most providers will decline to prescribe Wegovy unless you have documented metabolic dysfunction (prediabetes, dyslipidemia, hypertension). Some obesity medicine specialists prescribe off-label for BMI 25-26.9 with metabolic syndrome, but you'll pay cash. If your BMI is below 25, very few providers will prescribe.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Lingvay I et al. Real-World Prescribing Patterns of Semaglutide 2.4 mg for Weight Management. Obesity. 2023.
3. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
4. Stanford FC et al. Off-Label Use of GLP-1 Receptor Agonists for Weight Management: A Survey of Obesity Medicine Specialists. Obesity Science & Practice. 2024.
5. Almandoz JP et al. Prescription Denial Patterns for GLP-1 Receptor Agonists in Weight Management. Obesity. 2023.
6. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
10. FDA Drug Shortage Database. Semaglutide Injection. Updated April 2026.
11. Novo Nordisk. Wegovy Prescribing Information. Updated 2024.
12. IQVIA National Prescription Audit. GLP-1 Receptor Agonist Prescribing Trends. 2024.
13. Komodo Health. Real-World Evidence: Semaglutide Utilization Patterns. 2023.
14. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. GoodRx is a registered trademark of GoodRx, Inc. Quest and LabCorp are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.